Can This Combination Be Used?
Yes, a patient can take mirtazapine (Remeron), amitriptyline, and eszopiclone (Lunesta, not "remelton") together, but this requires careful monitoring due to additive CNS depression and specific pharmacokinetic interactions.
Key Safety Considerations
CNS Depression Risk
The FDA label for Lunesta explicitly warns that downward dose adjustment is recommended when eszopiclone is administered with agents having known CNS-depressant effects 1. Both mirtazapine and amitriptyline have sedative properties that will compound with eszopiclone's hypnotic effects, increasing risks of:
- Excessive somnolence
- Impaired motor and cognitive performance
- "Sleep-driving" and other complex behaviors (more likely when combining CNS depressants) 1
Pharmacokinetic Interactions
Research demonstrates that mirtazapine and amitriptyline do interact pharmacokinetically when combined. Specifically:
- Amitriptyline increases mirtazapine Cmax by 36% in males
- Mirtazapine increases amitriptyline Cmax by 23% in males and decreases it by 23% in females 2
While these changes are considered "minor" and the combination was tolerated in healthy subjects, the study authors concluded that "caution is warranted when combining amitriptyline and mirtazapine" 2.
Practical Dosing Algorithm
If prescribing this combination:
Start eszopiclone at 1 mg (not the standard 2 mg dose) due to CNS depressant coadministration 1
Use lower doses of both antidepressants than you would for monotherapy, particularly if the primary indication is sleep rather than depression
Avoid alcohol completely - the FDA label shows additive psychomotor impairment when eszopiclone is combined with ethanol 1
Monitor closely for:
- Excessive daytime sedation
- Falls risk (especially in elderly)
- Memory impairment
- Complex sleep behaviors
Clinical Context
The evidence shows that low-dose mirtazapine (7.5-15 mg) is effective for insomnia with clinically relevant improvement at 6 weeks 3, while low-dose amitriptyline (10-20 mg) showed statistical but not clinically relevant benefit 3. This suggests that if the goal is sleep improvement, mirtazapine alone with eszopiclone may be preferable to adding amitriptyline.
The combination of all three medications simultaneously represents polypharmacy that increases risk without clear evidence of superior benefit. Consider whether the patient truly needs all three agents or if optimization of one or two would be safer and equally effective.
Critical Pitfall to Avoid
Do not assume "low doses are safe" - even at reduced doses, the additive CNS depression is the primary concern, not just the individual drug effects. The FDA specifically addresses this for eszopiclone 1, and the research on mirtazapine-amitriptyline combinations emphasizes caution despite "minor" pharmacokinetic changes 2.